ASXL1 mutations that cause Bohring Opitz Syndrome (BOS) or acute myeloid leukemia share epigenomic and transcriptomic signatures
I. Lin, Z. Awamleh, A. Wei, B. Russell, R. A. Weksberg, V. A. Arboleda
This study compares epigenomic and transcriptomic changes in Bohring-Opitz Syndrome and AML with ASXL1 mutations, finding shared dysregulation and potential common therapeutic targets.
bioRxiv · Dec 15, 2022 · PreprintCancer Biology